J B Chemicals and Pharmaceuticals Ltd
NSE:JBCHEPHARM
J B Chemicals and Pharmaceuticals Ltd
Intangible Assets
J B Chemicals and Pharmaceuticals Ltd
Intangible Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Intangible Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
J B Chemicals and Pharmaceuticals Ltd
NSE:JBCHEPHARM
|
Intangible Assets
₹12.7B
|
CAGR 3-Years
8%
|
CAGR 5-Years
111%
|
CAGR 10-Years
N/A
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Intangible Assets
₹100.9B
|
CAGR 3-Years
47%
|
CAGR 5-Years
20%
|
CAGR 10-Years
N/A
|
|
|
Cipla Ltd
NSE:CIPLA
|
Intangible Assets
₹19.2B
|
CAGR 3-Years
5%
|
CAGR 5-Years
1%
|
CAGR 10-Years
26%
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Intangible Assets
₹136.8B
|
CAGR 3-Years
32%
|
CAGR 5-Years
18%
|
CAGR 10-Years
N/A
|
|
|
Lupin Ltd
NSE:LUPIN
|
Intangible Assets
₹25.2B
|
CAGR 3-Years
24%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Intangible Assets
₹40.4B
|
CAGR 3-Years
5%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
N/A
|
|
J B Chemicals and Pharmaceuticals Ltd
Glance View
In the bustling marketplace of India's pharmaceutical industry, J B Chemicals and Pharmaceuticals Ltd. has carved its niche, a testament to its strategic vision and operational prowess. Founded in 1976 by Janak Mehta, the company has grown from its humble beginnings into a leading player in both the domestic and international arenas. Originally rooted in the ethos of quality and innovation, it established a firm foothold in the pharmaceutical sector through a diverse portfolio that includes formulations, active pharmaceutical ingredients (APIs), and contract manufacturing. As a vertically integrated company, J B Chemicals leverages its ability to control the manufacturing process from start to finish, ensuring strict quality measures and cost efficiencies, vital in tackling industry competition and regulatory challenges. The heart of J B Chemicals’ revenue model is its well-rounded product line that spans a range of therapeutic categories, including gastrointestinal, cardiovascular, and anticold segments. Blockbuster brands like Cilacar and Metrogyl have propelled the company to the top ranks within India, while its export division flourishes, contributing significantly to total earnings. With footprints in more than 30 countries, particularly in Russia and South Africa, the company taps into the growing demand for generic medicines worldwide. Moreover, by embracing innovation and investing in research and development, J B Chemicals continues to introduce new and improved medical solutions, positioning itself as a dynamic player in meeting global healthcare needs.
See Also
What is J B Chemicals and Pharmaceuticals Ltd's Intangible Assets?
Intangible Assets
12.7B
INR
Based on the financial report for Dec 31, 2025, J B Chemicals and Pharmaceuticals Ltd's Intangible Assets amounts to 12.7B INR.
What is J B Chemicals and Pharmaceuticals Ltd's Intangible Assets growth rate?
Intangible Assets CAGR 5Y
111%
Over the last year, the Intangible Assets growth was -6%. The average annual Intangible Assets growth rates for J B Chemicals and Pharmaceuticals Ltd have been 8% over the past three years , 111% over the past five years .